MORE►
gene therapy
Left: Daniel Hargrove, co-founder and CEO of InterAct Therapeutics; Right: Isaac Chan, MD, PhD, Co-founder and CSO of InterAct Therapeutics [Photos: LinkedIn]
UTSW Spinout InterAct Therapeutics Selected by Cell & Gene Therapy Incubator Program
by Sandra Engelland | Dec 11, 2025
InterAct, which launched inside BioLabs at Pegasus Park, is a preclinical stage biotech company developing AAV8-based gene therapies for metastatic cancer, with an initial focus on breast cancer-derived liver metastases.
by Quincy Preston |
Jul 15, 2025
North Texas' Nanoscope just filed an FDA bid for its gene-agnostic therapy. If approved, it could help restore sight for people with inherited blindness, and potentially millions more with other retinal diseases.
MORE►
by Quincy Preston |
Sep 18, 2023
The deal with Fresenius Kabi aims to bring innovative cell and gene treatments closer to patients by advancing Lupagen’s proprietary cell and gene therapy delivery system, the companies said. Their "to the bedside" approach could help open cutting-edge treatments to local hospitals and patients worldwide.
MORE►
by Sandra Engelland |
Aug 18, 2023
MassChallenge will assemble human performance and sports tech innovators to redefine the bounds of the human condition in a new six-week, high-intensity program. Target technologies are applications in biotech, defense, healthcare, space, and sports.
Applications for the Dallas-based cohort are open through September 7.
Applications for the Dallas-based cohort are open through September 7.
MORE►
![R.A. Session II, president, CEO, and founder of Taysha Gene Therapies [Background image: Olena Yepifanova via iStock]](https://s24806.pcdn.co/wp-content/uploads/2020/04/TayshaGene-Session-970-1-940x436.jpg)
R.A. Session II, president, CEO, and founder of Taysha Gene Therapies [Background image: Olena Yepifanova via iStock]
Dallas Gene Therapy Startup Closes $95M Series B to Bolster its Initial Clinical Studies
by Quincy Preston and Alex Edwards | Aug 5, 2020
Taysha Gene Therapies, which was been operating in stealth with UT Southwestern until this April, plans to use the financing to advance its initial cohort of lead programs into its clinic. By the end of 2021, Taysha expects to file four Investigational New Drug applications.
MORE►
by Lance Murray |
Sep 13, 2019
In this weekly roundup of research and development activity in North Texas, you’ll also read about how an SMU professor and students from Garland High School are using smartphone data to monitor a local bridge’s health.
MORE►
by Lance Murray |
Sep 12, 2019
Together, the two companies aim to increase access to complex medications and ensure that patients more quickly receive the correct drug at the right time.
MORE►
by Natalie Le |
Jul 30, 2019
Providing integrated solutions ranging from discovery to engineering, biologics CRDMO LakePharma made its Dallas debut earlier this summer.
MORE►
